Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Perrone

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 19, 2016
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney diseaseJared J Grantham, Arlene B Chapman, Jaime Blais, et al.
Journal of the American Society of Nephrology : JASN|September 20, 2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with TolvaptanFouad T Chebib, Ronald D Perrone, Arlene B Chapman, et al.
Kidney360|January 14, 2025
Establishing Meaningful Patient-Centered Outcomes with Relevance for Patients with Polycystic Kidney Disease: Patient, Caregiver, and Researcher Priorities for Research in Polycystic Kidney DiseaseReem A Mustafa, Hassan Kawtharany, Mohamad A Kalot, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Kidney International Reports|March 20, 2023
Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial ParticipantsKenneth R Hallows, Kaleab Z Abebe, Hui Li, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2014
Filling the holes in cystic kidney disease researchLisa M Guay-Woodford, Elizabeth Henske, Peter Igarashi, et al.
Kidney360|September 30, 2022
Design and Basic Characteristics of a National Patient-Powered Registry in ADPKDElise Hoover, Ronald D Perrone, Chris Rusconi, et al.
Journal of the American Society of Nephrology : JASN|May 18, 2026
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseStephanie Lapierre-Nguyen, Zhiying You, Berenice Gitomer, et al.
Kidney International Reports|May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKDRonald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 19, 2016
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney diseaseJared J Grantham, Arlene B Chapman, Jaime Blais, et al.
Journal of the American Society of Nephrology : JASN|September 20, 2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with TolvaptanFouad T Chebib, Ronald D Perrone, Arlene B Chapman, et al.
Kidney360|January 14, 2025
Establishing Meaningful Patient-Centered Outcomes with Relevance for Patients with Polycystic Kidney Disease: Patient, Caregiver, and Researcher Priorities for Research in Polycystic Kidney DiseaseReem A Mustafa, Hassan Kawtharany, Mohamad A Kalot, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Kidney International Reports|March 20, 2023
Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial ParticipantsKenneth R Hallows, Kaleab Z Abebe, Hui Li, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2014
Filling the holes in cystic kidney disease researchLisa M Guay-Woodford, Elizabeth Henske, Peter Igarashi, et al.
Kidney360|September 30, 2022
Design and Basic Characteristics of a National Patient-Powered Registry in ADPKDElise Hoover, Ronald D Perrone, Chris Rusconi, et al.
Journal of the American Society of Nephrology : JASN|May 18, 2026
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseStephanie Lapierre-Nguyen, Zhiying You, Berenice Gitomer, et al.
Kidney International Reports|May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKDRonald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.
Pageof 13